Clinical Trial

Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to test a new experimental recombinant Poliomyelitis vaccine (rPV) in comparison to the commercially available inactivated poliovirus vaccine. The design of the study is double-blinded, randomised and active controlled. The active controlled product is considered the commercially available vaccine (IPOL).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-30.
Trial Details
NCT Number NCT07688369
Lead Sponsor Serum Institute of India Pvt. Ltd.
Conditions Polio Immunity
Enrollment 36 participants
Start Date 2026-07
Primary Completion 2026-11 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-10